

DAFTAR PUSTAKA

1. Wreksoatmodjo BR. Beberapa kondisi fisik dan penyakit yang merupakan faktor risiko gangguan fungsi kognitif. *Cermin Dunia Kedokteran*. 2014;41(1):25–32.
2. Dinas Kesehatan Provinsi Sumatera Barat. Riset Kesehatan Dasar (Riskesda). 2013.
3. Pelayanan Geriatri. Standar Nasional Akreditasi Rumah Sakit: Program Nasional Sasaran V. 2018.
4. Menteri Kesehatan Republik Indonesia. Penyelenggaraan Pelayanan Geriatri di Rumah Sakit. Peraturan Menteri Kesehatan Republik Indonesia Nomor 79 Tahun 2014.
5. Eshkoo SA, Hamid TA, Mun CY, Ng CK. Mild cognitive impairment and its management in older people. *Clinical Interventions in Aging*. 2015;10:687–93.
6. Forlenza OV, Diniz BS, Stella F, Teixeira AL, Gattaz WF. Mild cognitive impairment (part 1): clinical characteristics and predictors of demensia. *Revista Brasileira de Psiquiatria*. 2013;35:178–85.
7. Ciesielska N, Sokolowski R, Stemplowski W, Lakomski M, Zukow W, Kędziora-Kornatowska K. Diagnosis of mild cognitive impairment. *Journal of Health Sciences*. 2014;04(07):133–44.
8. Teng E, Tassniyom K, Lu PH. Reduced quality of life ratings in mild cognitive impairment: analyses of subject and informant responses. *Am J Geriatr Psychiatry*. 2012;20(12):1016–25.
9. Johansson M. Cognitive impairment and its consequences in everyday life. Thesis: Linköping University Medical Dissertation No. 1452. 2015.
10. Jekel K, Damian M, Hausner L, Bullock R, Connelly PJ, Dubois B et al. Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review. *Alzheimer's Research & Therapy*. 2015;7(17):1–20.
11. Friedman L. Evaluating the Montreal Cognitive Assessment (MoCA) and the Mini Mental State Exam (MMSE) for Cognitive Impairment Post Stroke: A

Validation Study against the Cognistat. Electronic Thesis and Dissertation Repository. 2012:1—90.

12. Soejono CH, Harimurti K, Setiati S, Damping CE. Pedoman Diagnosis dan Tatalaksana MCI & VCI. Konsensus Nasional PERGEMI. 2006:21.
13. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Chertkow H. The Montreal cognitive assessment, MoCA: A brief screening tool for mild cognitive impairment. *Journal of the American Geriatrics Society*. 2005;53(4):695—9.
14. Kim SY, Lim TS, Lee HY, Moon SY. Clustering mild cognitive impairment by mini-mental state examination. *Neurol Sci*. 2014;35(9): 1353—8.
15. Hampel H, Blennow K. CSF tau and β -amyloid as biomarkers for mild cognitive impairment. *Dialogues Clin Neurosci*. 2004;6:379—90.
16. Puzzo D, Arancio O. Amyloid- β Peptide: Dr. Jekyll or Mr. Hyde? *J Alzheimers Dis*. 2013;33(1):111—20.
17. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ et al. Association of low plasma $a\beta_{42}/a\beta_{40}$ ratios with increased imminent risk for mild cognitive impairment and alzheimer disease. *Arch Neurol*. 2007;64:354—62.
18. Yusuf RN. Hubungan konsumsi sumber asam lemak dengan gangguan fungsi kognitif pada lanjut usia. Tesis: Fakultas Kedokteran Universitas Andalas Bagian Pascasarjana Biomedik Padang. 2014.
19. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B et al. Evaluation of CSF-tau and CSFA as diagnostic markers for Alzheimer disease in clinical practice. *Arch Neurol*. 2001;58:373—9.
20. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, csf, and plasma amyloid b protein in the tg2576 transgenic mouse model of alzheimer's disease. *The Journal of Neuroscience*. 2001;21(2):372—81.
21. Pesaresi M, Lovati C, Bertora P, Mailland E, Galimberti D, Scarpini E et al. Plasma levels of β -amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. *Neurobiol Aging*. 2006;27:904—5.

22. Seppala TT, Herukka SK, Tervo S, Hallikainen M, Soininen H, Pirttila T. Plasma Ab42 and Ab40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study. *J Neurol Neurosurg Psychiatry*. 2010;1—5.
23. Luis CA, Abdullah L, Ait-Ghezala G, Mouzon B, Keegan AP, Crawford F et al. Feasibility of predicting MCI/AD using neuropsychological tests and serum β -amyloid. *International Journal of Alzheimer's Disease*. 2011;1—7.
24. Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A et al. Plasma β -amyloid in Alzheimer's disease and vascular disease. *Nature*. 2016;1—11.
25. Morris JC, Storandt M, Miller P, McKeel DW, Price JL, Rubin EH et al. Mild cognitive impairment represents early-stage alzheimer disease. *Arch Neurol*. 2001;58:397—405.
26. Van Dyck CH. Anti-amyloid-b monoclonal antibodies for alzheimer's disease: pitfalls and promise. *Biological Psychiatry*. 2018;83:311—9.
27. Panza F, Frisardi V, Imbimbo BP, Seripa D, Solfrizzi V, Pilotto A. Monoclonal antibodies against b-amyloid (Ab) for the treatment of Alzheimer's disease: the Ab target at a crossroads. *Expert Opin. Biol. Ther*. 2011;1—8.
28. Lumbantobing. *Kecerdasan Pada Usia Lanjut dan Dementia: Memori (Daya Ingat, Ingatan)*. Balai Penerbitan FKUI Jakarta. 2006.
29. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV et al. Current concept in mild cognitive impairment. *Arch Neurol*. 2001;58:1985—92.
30. Luck T, Lupp M, Briel S, Riedel-Heller SG. Incidence of mild cognitive impairment: a systematic review. *Dement Geriatr Cogn Disord*. 2010;29:164—75.
31. Diniz BS, Nunes PV, Yassuda M, Pereira FS, Flaks MK, Viola LF et al. Mild cognitive impairment: cognitive screening or neuropsychological assessment? *Rev Bras Psiquiatr*. 2008;30:316—21.

32. Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L. Mild cognitive impairment: a concept in evolution. *J Intern Med*. 2014;275(3):214–28.
33. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. *Arch neurol*. 1999;56:303–8.
34. Martini RD. Penurunan Fungsi Kognitif Pada Usia Lanjut: Deteksi Dan Tata Laksana. The Fourth Scientific Meeting on Psychosomatic Medicine. 2016:195–204.
35. Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Boeve BF et al. The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic Study of Aging. *Neurology*. 2012;78:342–51.
36. Caracciolo B, Palmer K, Monastero R, Winblad B, Bäckman L, Fratiglioni L. Occurrence of cognitive impairment and dementia in the community: a 9-year-long prospective study. *Neurology*. 2008;70:1778–85.
37. Jiankang L, Mori A. Stress, aging and brain oxidative damage. *Neurochemical Research*. 1999;24(11):1479–97.
38. Septiana AT, Asnani A. Antioxidan activity of *Sargassum duplicatum* seaweed extract. *Jurnal Teknologi Pertanian*. 2013;14(2):79–86.
39. Rissman RA, Trojanowski JQ, Shaw LM, Aisen PS. Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease. *J Neural Transm*. 2012;119(7):843–50.
40. Murphy MP, LeVine III H. Alzheimer's disease and the β amyloid peptide. *J Alzheimer Dis*. 2010;19(1):1–17.
41. Tang BL, Kumar R. Biomarkers of mild cognitive impairment and alzheimer's disease. *Ann Acad Med Singapore*. 2008;37:406–10.
42. Hartmann T, Bieger SC, Brühl B, Tienari PJ, Ida N, Allsop D et al. Distinct sites of intracellular production for Alzheimer's disease A beta 40/42 amyloid peptides. *Nature Medicine*. 1997;3(9):1016–20.

43. Syafrita Y. Hubungan usia penderita stroke iskemik dengan kadar beta-amyloid plasma. *Cermin Dunia Kedokteran*. 2015;22(10):732–5.
44. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B et al. Clearance of Alzheimer's amyloid-b 1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. *The Journal of Clinical Investigation*. 2000;106(12):1489–99.
45. Silverberg GD, Messier AA, Miller MC, Machan JT, Majmudar SS, Stopa EG et al. Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. *J Neuropathol Exp Neurol*. 2010;69(10):1034–43.
46. Silverberg GD, Miller MC, Messier AA, Majmudar S, Machan JT, Donahue JE et al. Amyloid deposition and influx transporter expression at the blood-brain barrier increase in normal aging. *J Neuropathol Exp Neurol*. 2010;69(1):98–108.
47. Formichi P, Battisti C, Radi E, Federico A. Cerebrospinal fluid tau, a β , and phosphorylated tau protein for the diagnosis of alzheimer's disease. *Journal Of Cellular Physiology*. 2006;208:39–46.
48. Murray AM, Barzilay JI, Williamson JD. Biomarker of renal function and cognitive impairment in patients with diabetes. *Diabetes care*. 2011;34(8):1827–33.
49. Tombaugh TN, McIntyre. The mini-mental state examination: a comprehensive review. *Journal American Geriatric Society*. 1993;40:922–35.
50. O'Bryant, Joy D, Glenn E. Detecting dementia with the mini-mental state examination in highly educated individuals. *Jama Neurology*. 2008;7:963–7.
51. Hye Choi S, Yong S Shim, Seung-Ho Ryu. Validation of the literacy independent cognitive assessment. *International Psychogeriatrics*. 2011;23:593–601.
52. Kolegium Psikiatri Indonesia. Program pendidikan dokter spesialis psikiatri. Modul psikiatri geriatri. 2008.
53. Forlenza OV, Diniz BS, Teixeira AL, Stella F, Gattaz W. Mild cognitive impairment (part 2): biological markers for diagnosis and prediction of dementia in Alzheimer's disease. *Revista Brasileira de Psiquiatria*. 2013;35:284–94.

54. Petersen RC, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, Smith GE et al. Mild cognitive impairment: ten years later. *Arch Neurol*. 2009;66(12):1447–55.
55. Kim B, Feldman EL. Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. *Experimental & Molecular Medicine*. 2015;47:1–10.
56. Sandhir R, Gupta S. Molecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisal. *World J Diabetes*. 2015;6(12):1223–42.
57. Carnevale D, Mascio G, D'Andrea I, Fardella V, Bell RD, Branchi I et al. Hypertension induces brain β -amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature. *Hypertension*. 2012;60:188–97.
58. Yaffe K, Weston A, Graff-Radford NR, Satterfield S, Simonsick EM, Younkin SG et al. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. *JAMA*. 2011;305(3):261–6.
59. Ruiz A, Pesini P, Espinosa A, Perez-Grijalba V, Valero S, Sotolongo-Grau O et al. Blood amyloid beta levels in healthy, mild cognitive impairment and alzheimer's disease individuals: replication of diastolic blood pressure correlations and analysis of critical covariates. *Plos One*. 2013;8(11):1–9.
60. Van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MMB. Plasma $a\beta_{40}$ and $a\beta_{42}$ and the risk of dementia: a prospective case-cohort study. *Lancet Neurol*. 2006;5:655–60.
61. Lui JK, Laws SM, Li Q, Villemagne VL, Ames D, Brown B et al. Plasma amyloid- β as a biomarker in alzheimer's disease: the aibl study of aging. *J Alzheimers Dis*. 2010;20:1233–42.
62. Ballesteros S, Mayas J, Reales M. Cognitive function in normal aging and in older adults with mild cognitive impairment. *Psicothema*. 2013;25(1):18–24.
63. Cosentino SA, Stern Y, Sokolov E, Scarmeas N. Plasma β -amyloid and cognitive decline. *Arch Neurol*. 2010;1–6.

64. Lambert JC, Schraen-Maschke S, Richard F, Fievet N, Rouaud O, Berr C et al. Association of plasma amyloid with risk of dementia. *Neurology*. 2009;73:847–53.
65. Petersen RC, Roberts RO, Knopman DS, Geda YE, Cha RH, Pankratz VS et al. Prevalence of mild cognitive impairment is higher in men. *Neurology*. 2010;75:889–97.
66. Li R, Singh M. Sex differences in cognitive impairment and alzheimer's disease. *Front Neuroendocrinol*. 2014;35(3):385–403.
67. Vina J, Lloret A. Why women have more alzheimer's disease than men: gender and mitochondrial toxicity of amyloid- β peptide. *J Alzheimers Dis*. 2010;20:527–33.
68. Hanon O, Vidal JS, Lehmann S, Bombois S, Allinquant B, Treluyer JM et al. Plasma amyloid levels within the alzheimer's process and correlations with central biomarkers. *Alzheimer's & Dementia*. 2018:1–11.
69. Sundelof J, Giedraitis V, Izarry MC, Sundstrom J, Ingelsson E, Ronnema E et al. Plasma amyloid and the risk of alzheimer disease and dementia in elderly men. *Arch Neurol*. 2008;65(2):256–63.
70. Bosma H, van Boxtel MPJ, Ponds RWHM, Houx PJH, Jolles J. Education and age-related cognitive decline: the contribution of mental workload. *Educational Gerontology*. 2003;29:165–73.
71. Zahodne LB, Stern Y, Manly JJ. Differing effects of education on cognitive decline in diverse elders with low versus high educational attainment. *Neuropsychology*. 2015;29(4):649–57.
72. Glymour MM, Tzourio C, Dufouil C. Is cognitive aging predicted by one's own or one's parents' educational level? Results from the three-city study. *Am J Epidemiol*. 2012;175(8):750–9.
73. Alley D, Suthers K, Crimmins E. Education and Cognitive Decline in Older Americans: Results From the AHEAD Sample. *Res Aging*. 2007;29(1):73–94.
74. Wilson RS, Hebert LE, Scherr PA, Barnes LL, Mendes de Leon CF, Evans DA. Educational attainment and cognitive decline in old age. *Neurology*. 2009;72:460–5.

75. Liao KM, Ho CH, Ko SC, Li CY. Increased risk of dementia in patients with chronic obstructive pulmonary disease. *Medicine*. 2015;94(23):1–5.
76. Vogels RLC, Scheltens P, Schroeder-Tanka JM, Weinstein HC. Cognitive impairment in heart failure: A systematic review of the literature. *European Journal of Heart Failure*. 2007;9:440–9.
77. Deckers K, Schievink SHJ, Rodriguez MMF, Oostenbrugge RJ, Boxtel MPJ, Verhey FRJ et al. Coronary heart disease and risk for cognitive impairment or dementia: Systematic review and meta-analysis. *Plos One*. 2017;1–15.
78. Risacher SL, Kim S, Shen L, Nho K, Foroud T, Green RC et al. The role of apolipoproteinE (APOE) genotype in early mild cognitive impairment(E-MCI). *Frontiers in Aging Neuroscience*. 2013;5(11):1–12.
79. Ewers M, Zhong Z, Burger K, Wallin A, Blennow K, Teipel SJ et al. Increased CSF-BACE 1 activity is associated with ApoE-e4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. *Brain*. 2008;131:1252–8.
80. Rembach A, Faux NG, Watt AD, Pertile KK, Rumble RL, Trounson BO et al. Changes in plasma amyloid beta in a longitudinal study of aging and alzheimer's disease. *Alzheimer's & Dementia*. 2014:53–61.
81. Poljak A, Crawford JD, Smythe GA, Brodaty H, Slavin MJ, Kochan NA et al. The relationship between plasma $a\beta$ levels, cognitive function and brain volumetrics: sydney memory and ageing study. *Curr Alzheimer Res*. 2016;13:243–55.
82. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in alzheimer disease. *Arch Neurol*. 2000;57:100–5.